{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:35:45Z","timestamp":1794242145457,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04072-x","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T08:15:50Z","timestamp":1766823350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective analysis of diffuse large B-cell lymphoma treated with the R-CHOP regimen at a Malaysian tertiary hospital"],"prefix":"10.1186","volume":"24","author":[{"given":"Alvin Jung Mau","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze Shin","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Wan Chieng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ping","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"4072_CR1","unstructured":"Summary of the Malaysian Cancer Registry 2017\u20132021. National Cancer Registry Department, Institut Kanser Negara, Ministry of Health, Malaysia. 2024. https:\/\/nci.moh.gov.my\/images\/pdf_folder\/SUMMARY-OF-MALAYSIA-NATIONAL-CANCER-REGISTRY-REPORT-2017-2021.pdf. Accessed 27 Dec 2024."},{"key":"4072_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"4072_CR3","first-page":"1","volume":"45","author":"KG Lim","year":"2023","unstructured":"Lim KG, Sumera A, Burud IAS, Venkateswaran SP. Diffuse large B-cell lymphoma research in Malaysia: a review. Malays J Pathol. 2023;45:1\u201310.","journal-title":"Malays J Pathol"},{"key":"4072_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"issue":"13","key":"4072_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z, Clausen MR, Al-Mashhadi AL, Pedersen RS, et al. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J. 2023;13(13):157.","journal-title":"Blood Cancer J"},{"key":"4072_CR6","first-page":"181","volume":"35","author":"K Matsumoto","year":"2018","unstructured":"Matsumoto K, Fujisawa S, Ando T, Koyama M, Koyama S, Ishii Y, et al. Anemia associated with worse outcome in diffuse large B-cell lymphoma patients: a single-center retrospective study. Turkish J Haematol. 2018;35:181\u20134.","journal-title":"Turkish J Haematol"},{"key":"4072_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/09537104.2018.1499889","volume":"30","author":"S Nakayama","year":"2019","unstructured":"Nakayama S, Matsuda M, Adachi T, Sueda S, Ohashi Y, Awaji S, et al. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Platelets. 2019;30:637\u201345.","journal-title":"Platelets"},{"key":"4072_CR8","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3109\/10428194.2015.1010078","volume":"56","author":"AO Gang","year":"2015","unstructured":"Gang AO, Pedersen M, d\u2019Amore F, Pedersen LM, Jensen BA, Jensen P, et al. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leuk Lymphoma. 2015;56:2556\u201362.","journal-title":"Leuk Lymphoma"},{"key":"4072_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.13116","volume":"168","author":"T Melchardt","year":"2015","unstructured":"Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tr\u00e4nkenschuh W, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and \u03b22-microglobulin. Br J Haematol. 2015;168:239\u201345.","journal-title":"Br J Haematol"},{"key":"4072_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.blre.2018.03.005","volume":"32","author":"JC Wight","year":"2018","unstructured":"Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev. 2018;32:400\u201315.","journal-title":"Blood Rev"},{"key":"4072_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"4072_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jclinpath-2019-205837","volume":"72","author":"N Masir","year":"2019","unstructured":"Masir N, Akhter A, Roshan TM, Florence CS, Abdul-Rahman F, Tumian NR, et al. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy. J Clin Pathol. 2019;72:630\u20135.","journal-title":"J Clin Pathol"},{"key":"4072_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Brier J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"4072_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, \u00d6sterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"4072_CR15","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","volume":"26","author":"DO Persky","year":"2008","unstructured":"Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258\u201363.","journal-title":"J Clin Oncol"},{"key":"4072_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cam4.2008","volume":"8","author":"M D\u0142ugosz-Danecka","year":"2019","unstructured":"D\u0142ugosz-Danecka M, Szmit S, Og\u00f3rka T, Skotnicki AB, Jurczak W. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. Cancer Med. 2019;8:1103\u20139.","journal-title":"Cancer Med"},{"key":"4072_CR17","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303. J Clin Oncol. 2019;37:1790\u20139.","journal-title":"J Clin Oncol"},{"key":"4072_CR18","first-page":"3602","volume":"15","author":"M Horvat","year":"2018","unstructured":"Horvat M, Zadnik V, \u0160etina TJ, Boltezari L, Golicnik JP, Novakovic S, et al. Diffuse large B-cell lymphoma: 10 years\u2019 real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncol Lett. 2018;15:3602\u20139.","journal-title":"Oncol Lett"},{"key":"4072_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gasoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"4072_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12725-5","volume":"24","author":"MK Mwalim","year":"2024","unstructured":"Mwalim MK, Leong E, Ong SK, Mohamad Z. Non-Hodgkin lymphoma incidence, mortality, and trends in Brunei Darussalam from 2011 to 2020. BMC Cancer. 2024;24:994.","journal-title":"BMC Cancer"},{"issue":"1","key":"4072_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89316-y","volume":"11","author":"SN Pei","year":"2021","unstructured":"Pei SN, Wang MC, Ma MC, Kuo CY, Liao CK, Qiu H, et al. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Sci Rep. 2021;11(1):10069.","journal-title":"Sci Rep"},{"key":"4072_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00265","volume":"8","author":"M Pavlovsky","year":"2022","unstructured":"Pavlovsky M, Cubero D, Agreda-Vasquez GP, Enrico A, Mela-Osorio MJ, San Sebasti\u00e1n JA, et al. Clinical outcomes of patients with B-cell non-Hodgkin lymphoma in real-world settings: findings from the Hemato-Oncology Latin America Observational Registry Study. JCO Global Oncol. 2022;8:e2100265.","journal-title":"JCO Global Oncol"},{"key":"4072_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/bjh.17206","volume":"193","author":"AA Sabaa","year":"2021","unstructured":"Sabaa AA, M\u00f6rth C, Hasselblom S, Hedstr\u00f6m G, Flogeg\u00e5rd M, Stern M, et al. Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. Br J Haematol. 2021;193:906\u201314.","journal-title":"Br J Haematol"},{"key":"4072_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jha2.61","volume":"1","author":"K Hohloch","year":"2020","unstructured":"Hohloch K, Ziepert M, Truemper L, Buske C, Held G, Poeschel V, et al. Low serum albumin is a independent risk factor in elderly patients with aggressive B-cell lymphoma: results from prospective trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group. EJHaem. 2020;1:181\u20137.","journal-title":"EJHaem"},{"key":"4072_CR25","first-page":"1","volume":"16","author":"H Kaneko","year":"2022","unstructured":"Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, et al. Serum albumin levels strongly predict survival outcome of elderly patients with diffuse large B-cell lymphoma treated with rituximab-combined chemotherapy. Int J Hematol Oncol Stem Cell Res. 2022;16:1\u20138.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"4072_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00277-014-2031-2","volume":"93","author":"S Dalia","year":"2014","unstructured":"Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014;93:1305\u201312.","journal-title":"Ann Hematol"},{"key":"4072_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.leukres.2018.07.014","volume":"71","author":"SH Kim","year":"2018","unstructured":"Kim SH, Go SI, Seo J, Kang MH, Park SW, Kim HG, et al. Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2018;71:100\u20135.","journal-title":"Leuk Res"},{"key":"4072_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.","journal-title":"Nutr J"},{"key":"4072_CR29","first-page":"453","volume":"13","author":"PT Lam","year":"2007","unstructured":"Lam PT, Leung MW, Tse CY. Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Med J. 2007;13:453\u20139.","journal-title":"Hong Kong Med J"},{"key":"4072_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/014860710302700110","volume":"207","author":"CG Lis","year":"2003","unstructured":"Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr. 2003;207:10\u20135.","journal-title":"J Parenter Enteral Nutr"},{"key":"4072_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hon.2233","volume":"34","author":"O Bairey","year":"2016","unstructured":"Bairey O, Shacham-Abulafia A, Shpiberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34:184\u201392.","journal-title":"Hematol Oncol"},{"key":"4072_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0885-3924(00)00199-8","volume":"20","author":"RJ Dunlop","year":"2000","unstructured":"Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage. 2000;20:214\u201332.","journal-title":"J Pain Symptom Manage"},{"key":"4072_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(85)91447-3","volume":"1","author":"A Fleck","year":"1985","unstructured":"Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985;1:781\u20134.","journal-title":"Lancet"},{"key":"4072_CR34","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373\u201380.","journal-title":"J Clin Oncol"},{"key":"4072_CR35","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.7314\/APJCP.2014.15.4.1703","volume":"15","author":"GG Gan","year":"2014","unstructured":"Gan GG, Subramaniam R, Bee PC, Chin EFM, Abdul-Halim H, Tai MC. Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients. Asian Pac J Cancer Prev. 2014;15:1703\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4072_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"4072_CR37","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med"},{"key":"4072_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascyone RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04072-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:34:04Z","timestamp":1767846844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4072"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04072-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}